• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Additive Manufacturing (AM)

Additive Manufacturing (AM)

AM showcases the latest technology and industry developments with in-depth case studies, resources, interviews with experts and events.

    • CHANNEL
      • Aerospace
      • Automotive
      • Energy
      • Medical
      • Innovation
    • TOPICS
      • Design
      • Management
      • Materials
      • Post Processing
      • Processes
      • Quality Management Systems
      • Regulatory & Standards
      • Software
      • Workforce Development
    • NEWS
    • EVENTS
      • Conferences
      • Virtual Events
      • Webinars
      • Industry Events
      • On-Demand
      • Add Your Event
    • MEDIA
      • AM News LIVE
      • AM Voices
      • Podcast
      • Video
    • RESOURCES

    OssDsign Reaches Milestone of 500 Patients Treated with OssDsign® Catalyst in the U.S.

    OssDsign AB announced that 500 patients have now been treated in the U.S. with the nanosynthetic bone graft, OssDsign Catalyst.

    Uppsala,/January 9, 2023 — OssDsign AB announced that 500 patients have now been treated in the U.S. with the nanosynthetic bone graft, OssDsign Catalyst. Since the launch, awareness of the product has increased exponentially, which is reflected in the growing number of patients who benefit from the treatment. Reaching the 500-patient milestone is a significant achievement in the effort to expand the product’s presence in the U.S. market.

    OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue.

    “Since June 2022, where we reached the first 100 patients, momentum has significantly accelerated. The rapid growth in the number of patients treated emphasizes the traction of OssDsign Catalyst and the increasing interest from surgeons in using the product for spinal fusion surgeries. Together with the post-market safety report and recent clinical data published on OssDsign Catalyst, reaching the 500-patient milestone is creating a stronger basis for the continued commercialization,” says Morten Henneveld, CEO of OssDsign.

    The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION (NCT05114135), the premarket clinical trial, in which patient enrolment was completed in April 2022, run under the leadership of world-leading experts in spinal surgery.

    related /

  • OssDsign AB announced the company has reached the milestone of 100 patients in the multi-center, prospective spinal fusion registry, PROPEL. Spinal Fusion Registry: OssDsign Reaches Milestone of 100 Patients in its PROPEL Registry Ahead of Time
  • OssDsign Enrolls the First Patient to the Multi-center Prospective Spinal Fusion Registry PROPEL in the U.S.
  • Data, based on 1,995 surgeries, shows the frequency of infections leading to cranial implant removal was 1.4%. Post-Market Surveillance Continues to Show Low Observed Complication Rates with OssDsign Cranial PSI
  • Filed Under: News

    Primary Sidebar

    events /

    upcoming webinars /

    • There are no upcoming events.

    on demand /

    • SOLIDWORKS Certification Tips and Tricks

      January 24 @ 11:00 am - 12:00 pm EST
    • Is there really a use for additive manufacturing in commercial vehicles?

      December 7, 2022 @ 1:00 pm - 2:00 pm EST
    • Development of Metal Additive Manufacturing for Naval Shipbuilding

      December 1, 2022 @ 1:00 pm - 2:00 pm EST

    Footer

    AM-logo_RGB_500_white

    With dozens of innovative products, materials, software, and applications being launched constantly, you can rely on AdditiveManufacturing.com to keep you ahead of the curve.

    stay connected /

    recent /

    • Watch On-Demand: AM News LIVE: EP22 – Anne Pauley & Michael Molitch-Hou – CES, TIPE, AMS – Monday, January 23rd 2023
    • Workforce and Leadership: AM News Roundup for January 9-20, 2023
    • Dennis Fehr, Seasoned Financial Executive Joins 6K as Chief Financial Officer and Rob Davies, Manufacturing Expert, Joins 6K Energy as Chief Operating Officer
    • BIRD – Israel-U.S. Binational Industrial R&D Foundation to invest $8.4 million in 9 new projects
    • Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine
    • IperionX Wins U.S. Air Force Titanium Recycling Challenge
    • Essentium Expands Global Executive Leadership
    • Student Team Uses Micro Metal 3D Printing for Microgravity Experiment

    topics /

    • Applications
    • Design
    • Materials
    • Post Processing
    • Processes
    • Quality Management Systems
    • Regulatory & Standards
    • Software

    media /

    • Watch On-Demand: AM News LIVE: EP22 – Anne Pauley & Michael Molitch-Hou – CES, TIPE, AMS – Monday, January 23rd 2023
    • AM Materials Chat: 6K onsite at Formnext 2022 – AM Voices Podcast – Frank Roberts, President of 6K Additive
    • Watch On-Demand: AM News LIVE: EP21 – Sintavia – Brian R. Neff – Monday, January 9th 2023
    • Formnext 2022 flashback: Uniformity Labs, CEO Adam Hopkins on LPBF materials for 3D printing
    • AM Materials Chat: Uniformity Labs onsite at Incodema3D – AM Voices video podcast – Adam Hopkins, CEO at Uniformity Labs
    • AM Materials Chat: Elementum3D onsite at Incodema3D for AM Voices video podcast
    • AM Video Interview: Dr. Jason Rolland, SVP of Materials at Carbon
    • Watch On-Demand: AM News LIVE, EP20 – End Of Year Episode – 2022 Review with Friends

    Copyright © 2023 Metrix Connect, LLC

    • Advertise
    • About Us
    • Privacy Policy
    • Terms of Use
    • Editorial Guidelines
    • Code of Conduct
    • Contact